# US 2005/0089518 A1 · Prospective identification and characterization of breast cancer stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0089518 A1
- Document ID: US20050089518A1
- Status: Published application
- Kind: A1
- Application number: 10/497,791
- Filed: 2002-12-06
- Published: 2005-04-28
- Earliest claimed: 2001-12-07
- Inventors: Michael Clarke; Max Wicha; Muhammad Al-Hajj
- Web page: https://patentgrep.com/patent/US20050089518A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/1703: {from vertebrates}
- A61K 47/6897: {Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 16/3015: {Breast}
- C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells}
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Human breast tumors contain hetrogeneous cancer cells. using an animal xenograft model in which human breast cancer cells were grown in immunocompromised mice we found that only a small minority of breast cancer cells had capacity to form new tumors. The ability to form new tumors was not a slochastic property, rather certain populations of cancer cells were depleted for the ability to form new tumors, while other populations were enriched for the ability to form new tumors. Tumorigenic cells could be distinguished from non-tumorigenic cancer cells based on surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD4430CD24−/lowLINEAGE A few as 100 cells from this population were able to form tumors the animal xenograft model, while tens of thousands of cells from non-tumorigenic populations failed to form tumors. The tumorigenic cells could be serially passaged, each time generating new tumors containing and expanded numbers of CD44+CD24 Lineage tumorigenic cells as well as phenotypically mixed populations of non-tumorigenic cancer cells. This is reminiscent of the ability of normal stem cells to self-renew and differentiate. The expression of potential therapeutic targets also differed between the tumorigenic and non-tumorigenic populations. Notch activation promoted the survival of the tumorigenic cells, and a blocking antibody against Notch 4 induced tumorigenic breast cancer cells to undergo apoptosis.

## Claims

### Claim 1

A method for reducing the size of a solid tumor, comprising the step of:
contacting the cells of the solid tumor with a therapeutically effective amount of an agent directed against a Notch4 polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is an amount sufficient to cause cell death of or inhibit the proliferation of solid tumor stem cells in the solid tumor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent is an antibody, peptide or small molecule directed against a Notch4 polypeptide.

### Claim 4 (depends on 3)

The method of claim 3, wherein the antibody, peptide or small molecule is directed against the extracellular domain of Notch4.

### Claim 5

A method for reducing the size of a solid tumor, comprising:
contacting the cells of the solid tumor with a therapeutically effective amount of an agent that modulates the activity of a Notch4 ligand.

### Claim 6 (depends on 5)

The method of claim 5, wherein the Notch4 ligand is selected from the group consisting of Delta 1, Delta 2, Delta-like ligand 4 (D114), Jagged 1 and Jagged 2.

### Claim 7 (depends on 5)

The method of claim 5, wherein the agent is a Notch ligand agonist.

### Claim 8 (depends on 5)

The method of claim 5, wherein the agent is a Notch ligand antagonist.

### Claim 9

A method for reducing the size of a solid tumor, comprising:
contacting the cells of the solid tumor with a therapeutically effective amount of an agent that modulates the activity of Maniac Fringe.

### Claim 10 (depends on 9)

The method of claim 9, wherein the agent is a Maniac Fringe agonist.

### Claim 11 (depends on 9)

The method of claim 9, wherein the agent is a Maniac Fringe antagonist.

### Claim 12

A method for killing or inhibiting the proliferation of solid tumor stem cells, comprising the step of:
contacting the cells of a solid tumor with an agent or combination of agents selectively targeted to the solid tumor stem cells of the solid tumor, wherein the agent or combination of agents kills or inhibits the proliferation of solid tumor stem cells.

### Claim 13 (depends on 12)

The method of claim 12, further comprising the step of:
identifying the death of or the prevention of the growth of solid tumor stem cells in the solid tumor following contact by the agent or combination of agents.

### Claim 14 (depends on 12)

The method of claim 12, wherein the killing is by the activation of cell death in the solid tumor stem cells.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cell death is apoptosis.

### Claim 16 (depends on 12)

The method of claim 12, wherein the agent or combination of agents inhibits Notch4 signaling.

### Claim 17 (depends on 12)

The method of claim 12, wherein the agent is an antibody, peptide or small molecule directed against a Notch4 polypeptide.

### Claim 18 (depends on 12)

The method of claim 12, wherein the antibody, peptide or small molecule is directed against the extracellular domain of Notch4.

### Claim 19 (depends on 12)

The method of claim 12, wherein the agent or combination of agents modulates the activity of a Notch4 ligand.

### Claim 20 (depends on 19)

The method of claim 19, wherein the Notch4 ligand is selected from the group consisting of Delta 1, Delta 2, Delta-like ligand 4 (D114), Jagged 1 and Jagged 2.

### Claim 21 (depends on 12)

The method of claim 12, wherein the agent or combination of agents modulates the activity of Maniac Fringe.

### Claim 22 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells express at least one marker selected from the group consisting of CD44, epithelial specific antigen (ESA), and B38.1.

### Claim 23 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells express the cell surface marker CD44.

### Claim 24 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells express the cell surface marker epithelial specific antigen (ESA).

### Claim 25 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells express the cell surface marker B38.1.

### Claim 26 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells express lower levels of the marker CD24 than the mean expression of CD24 by non-tumorigenic cancer cells of the solid tumor.

### Claim 27 (depends on 12)

The method of claim 12, wherein the solid tumor stem cells fail to express at least one LINEAGE marker selected from the group consisting of CD2, CD3, CD10, CD14, CD16, CD31, CD45, CD64, and CD140b.

### Claim 28 (depends on 12)

The method of claim 12, wherein the solid tumor is an epithelial cancer or a sarcoma

### Claim 29 (depends on 28)

The method of claim 28, wherein the epithelial cancer is a breast cancer or an ovarian cancer.

### Claim 30

A method for reducing the size of a solid tumor, comprising the step of:
contacting the cells of the solid tumor in vivo with an agent or combination of agents selectively targeted to the solid tumor stem cells of the solid tumor, wherein the agent or combination of agents kills or inhibits the proliferation of solid tumor stem cells.

### Claim 31 (depends on 30)

The method of claim 30, further comprising the step of:
identifying the death of or the prevention of the growth of solid tumor stem cells in the solid tumor following contact by the agent or combination of agents.

### Claim 32 (depends on 30)

The method of claim 30, wherein the killing is by the activation of cell death in the solid tumor stem cells.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cell death is apoptosis.

### Claim 34 (depends on 30)

The method of claim 30, wherein the agent or combination of agents inhibits Notch-4 signaling.

### Claim 35 (depends on 30)

The method of claim 30, wherein the agent is an antibody, peptide or small molecule directed against a Notch4 polypeptide.

### Claim 36 (depends on 35)

The method of claim 35, wherein the antibody, peptide or small molecule is directed against the extracellular domain of Notch4.

### Claim 37 (depends on 30)

The method of claim 30, wherein the agent or combination of agents modulates the activity of a Notch ligand.

### Claim 38 (depends on 30)

The method of claim 30, wherein the Notch4 ligand is selected from the group consisting of Delta 1, Delta 2, Delta-like ligand 4 (D114), Jagged 1 and Jagged 2.

### Claim 39 (depends on 30)

The method of claim 30, wherein the agent or combination of agents modulates the activity of Maniac Fringe.

### Claim 40 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells express at least one marker selected from the group consisting of CD44, epithelial specific antigen (ESA). and B38.1.

### Claim 41 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells express the cell surface marker CD44.

### Claim 42 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells express the cell surface marker epithelial specific antigen (ESA).

### Claim 43 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells express the cell surface marker B38.1.

### Claim 44 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells fail to express at least one LINEAGE marker selected from the group consisting of CD2, CD3, CD10, CD14, CD16, CD31, CD45, CD64, and CD140b.

### Claim 45 (depends on 30)

The method of claim 30, wherein the solid tumor stem cells express lower levels of the marker CD24 than the mean expression of CD24 by non-tumorigenic cancer cells of the solid tumor.

### Claim 46 (depends on 30)

The method of claim 30, wherein the solid tumor is an epithelial cancer or a sarcoma.

### Claim 47 (depends on 46)

The method of claim 46, wherein the epithelial cancer is a breast cancer or an ovarian cancer.

### Claim 48

A method for selectively targeting a solid tumor stem cell, comprising the steps of:
(a) identifying a marker present on a solid tumor stem cell;
(b) obtaining a biomolecule or set of biomolecules that selectively binds to the marker present on the solid tumor stem cell.

### Claim 49 (depends on 48)

The method of claim 48, wherein the biomolecule genetically modifies the targeted solid tumor stem cell.

### Claim 50 (depends on 49)

The method of claim 49, wherein the genetic modification results in solid tumor stem cell death.

### Claim 51 (depends on 48)

The method of claim 48 wherein the biomolecule or set of biomolecules comprises a bi-specific conjugate.

### Claim 52 (depends on 48)

The method of claim 48, wherein the biomolecule or set of biomolecules comprises an adenoviral vector.

### Claim 53 (depends on 49)

The method of claim 49, wherein the adenoviral vector is selectively targeted to a solid tumor stem cell.

### Claim 54

A biomolecule or set of biomolecules that is selectively targeted to solid tumor stem cell.

### Claim 55 (depends on 54)

The method of claim 54, wherein the biomolecule genetically modifies the targeted solid tumor stem cell.

### Claim 56 (depends on 55)

The method of claim 55, wherein the genetic modification results in solid tumor stem cell death.

### Claim 57 (depends on 54)

The method of claim 54, wherein the biomolecule or set of biomolecules comprises a bi-specific conjugate.

### Claim 58 (depends on 54)

The method of claim 54, wherein the biomolecule or set of biomolecules comprises an adenoviral vector.

### Claim 59 (depends on 58)

The method of claim 58, wherein the adenoviral vector is selectively targeted to a solid tumor stem cell.

### Claim 60

A method for forming a tumor in an animal, comprising:
introducing a cell dose of purified solid tumor stem cells into the animal, wherein:
(a) the solid tumor stem cell is derived from a solid tumor;
(b) the solid tumor stem cell population is enriched at least 2-fold relative to unfractionated tumor cells.

### Claim 61 (depends on 60)

The method of claim 60, wherein the animal is an immunocompromised animal.

### Claim 62 (depends on 60)

The method of claim 60, wherein the animal is a mammal.

### Claim 63 (depends on 62)

The method of claim 62, wherein the mammal is an immunocompromised mammal.

### Claim 64 (depends on 62)

The method of claim 62, wherein the mammal is a mouse.

### Claim 65 (depends on 64)

The method of claim 64, wherein the mouse is an immunocompromised mouse.

### Claim 66 (depends on 65)

The method of claim 65, wherein the immunocompromised mouse is selected from the group consisting of nude mouse, SCID mouse, NOD/SCID mouse, Beige/SCID mouse; and β2 microglobin deficient NOD/SCID mouse.

### Claim 67 (depends on 60)

The method of claim 60, wherein the number of cells in the cell dose is between about 100 cells and about 5×105 cells.

### Claim 68 (depends on 60)

The method of claim 60, wherein the number of cells in the cell dose is about between about 100 cells and 500 cells.

### Claim 69 (depends on 60)

The method of claim 60, wherein the number of cells in the cell dose is between about 100 cells and 200 cells.

### Claim 70 (depends on 60)

The method of claim 60, wherein the number of cells in the cell dose is about 100 cells.

### Claim 71 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell expresses at least one marker selected from the group consisting of CD44, epithelial specific antigen (ESA), and B38.1.

### Claim 72 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell expresses the cell surface marker CD44.

### Claim 73 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell expresses the cell surface marker epithelial specific antigen (ESA).

### Claim 74 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell expresses the cell surface marker B38.1.

### Claim 75 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell expresses lower levels of the marker CD24 than the mean expression of CD24 by non-tumorigenic cancer cells derived from the solid tumor.

### Claim 76 (depends on 60)

The method of claim 60, wherein the solid tumor stem cell does not express detectable levels of one or more LINEAGE markers, wherein a LINEAGE marker is selected from the group consisting of CD2, CD3, CD10, CD14, CD16, CD31, CD45, CD64, and CD140b.
